{"id":43240,"date":"2025-10-14T14:34:18","date_gmt":"2025-10-14T06:34:18","guid":{"rendered":"https:\/\/flcube.com\/?p=43240"},"modified":"2025-10-14T14:34:19","modified_gmt":"2025-10-14T06:34:19","slug":"revir-therapeutics-secures-fda-orphan-drug-designation-for-rtx%e2%80%91117-targeting-charcot%e2%80%91marie%e2%80%91tooth-disease","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43240","title":{"rendered":"ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease"},"content":{"rendered":"\n<p><strong>ReviR Therapeutics<\/strong> announced today that the U.S. Food and Drug Administration (FDA) has granted <strong>Orphan Drug Designation (ODD)<\/strong> to its small\u2011molecule candidate <strong>RTX\u2011117<\/strong> for the treatment of <strong>Charcot\u2011Marie\u2011Tooth (CMT) disease<\/strong>. The company plans to launch a Phase\u202f1 safety study in healthy volunteers in Q1\u202f2026, followed by a Phase\u202f1b\/2a trial in CMT patients as scheduled.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-key-milestones\">Key Milestones<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>FDA Orphan Drug Designation<\/strong> \u2013 RTX\u2011117 is now eligible for regulatory incentives, including 7\u202fyears of market exclusivity, reduced fees, and potential tax credits.<\/li>\n\n\n\n<li><strong>Rapid Development Timeline<\/strong> \u2013 Leveraging an AI\u202f+\u202frobotic discovery platform from partner <strong>XtalPi<\/strong>, the molecule was identified and advanced to preclinical testing within eight months of project kickoff.<\/li>\n\n\n\n<li><strong>First AI\u2011Developed Small\u2011Molecule Therapy for CMT<\/strong> \u2013 RTX\u2011117 represents a historic first for both the disease and Chinese\u2011domestic innovation, marking the launch of a Category\u202f1 innovative drug in the region.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-scientific-rationale\">Scientific Rationale<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism of Action<\/strong> \u2013 RTX\u2011117 targets the <strong>Integrated Stress Response (ISR)<\/strong> by activating eIF2B, thereby restoring normal mRNA translation, re\u2011establishing protein homeostasis, and improving neuromuscular function.<\/li>\n\n\n\n<li><strong>Preclinical Efficacy<\/strong> \u2013 In rodent models of CMT, RTX\u2011117 produced robust therapeutic benefits, slowing disease progression and demonstrating substantial safety margins.<\/li>\n\n\n\n<li><strong>Unmet Need<\/strong> \u2013 CMT affects >\u202f2.6\u202fmillion people worldwide and currently lacks disease\u2011modifying therapies; RTX\u2011117 aims to fill this critical gap.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Focus<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Phase\u202f1 (Safety &amp; PK)<\/strong><\/td><td>Healthy volunteers<\/td><td>Q1\u202f2026<\/td><\/tr><tr><td><strong>Phase\u202f1b\/2a (Proof\u2011of\u2011Concept)<\/strong><\/td><td>CMT patients<\/td><td>Q3\u202f2026 onward<\/td><\/tr><tr><td><strong>Phase\u202f2\/3 (Efficacy &amp; Confirmation)<\/strong><\/td><td>Expanded patient cohorts<\/td><td>2028\u20112030<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p>ReviR Therapeutics is coordinating with the FDA to ensure a streamlined regulatory pathway and is engaging with patient advocacy groups to support trial recruitment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-revir-therapeutics\">About ReviR Therapeutics<\/h3>\n\n\n\n<p>ReviR Therapeutics is a China\u2011based biopharmaceutical company focused on developing small\u2011molecule therapeutics for rare and neuro\u2011degenerative diseases. The company combines deep scientific expertise with advanced AI\u2011driven discovery platforms to accelerate drug development.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-about-rtx-117\">About RTX\u2011117<\/h3>\n\n\n\n<p>RTX\u2011117 is a first\u2011in\u2011class, oral, small\u2011molecule therapy designed to modulate the ISR pathway in Charcot\u2011Marie\u2011Tooth disease, offering a novel mechanism for disease modification.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43241,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[24,3225,696],"class_list":["post-43240","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-rare-orphan-disease-drugs","tag-revir-therapeutics","tag-xtalpi"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its small\u2011molecule candidate RTX\u2011117 for the treatment of Charcot\u2011Marie\u2011Tooth (CMT) disease. The company plans to launch a Phase\u202f1 safety study in healthy volunteers in Q1\u202f2026, followed by a Phase\u202f1b\/2a trial in CMT patients as scheduled.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43240\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease\" \/>\n<meta property=\"og:description\" content=\"ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its small\u2011molecule candidate RTX\u2011117 for the treatment of Charcot\u2011Marie\u2011Tooth (CMT) disease. The company plans to launch a Phase\u202f1 safety study in healthy volunteers in Q1\u202f2026, followed by a Phase\u202f1b\/2a trial in CMT patients as scheduled.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43240\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-14T06:34:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-14T06:34:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1403.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43240#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43240\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease\",\"datePublished\":\"2025-10-14T06:34:18+00:00\",\"dateModified\":\"2025-10-14T06:34:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43240\"},\"wordCount\":352,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43240#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1403.webp\",\"keywords\":[\"Rare \\\/ orphan disease drugs\",\"ReviR Therapeutics\",\"Xtalpi\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43240#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43240\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43240\",\"name\":\"ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43240#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43240#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1403.webp\",\"datePublished\":\"2025-10-14T06:34:18+00:00\",\"dateModified\":\"2025-10-14T06:34:19+00:00\",\"description\":\"ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its small\u2011molecule candidate RTX\u2011117 for the treatment of Charcot\u2011Marie\u2011Tooth (CMT) disease. The company plans to launch a Phase\u202f1 safety study in healthy volunteers in Q1\u202f2026, followed by a Phase\u202f1b\\\/2a trial in CMT patients as scheduled.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43240#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43240\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43240#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1403.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1403.webp\",\"width\":1080,\"height\":608,\"caption\":\"ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43240#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease - Insight, China&#039;s Pharmaceutical Industry","description":"ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its small\u2011molecule candidate RTX\u2011117 for the treatment of Charcot\u2011Marie\u2011Tooth (CMT) disease. The company plans to launch a Phase\u202f1 safety study in healthy volunteers in Q1\u202f2026, followed by a Phase\u202f1b\/2a trial in CMT patients as scheduled.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43240","og_locale":"en_US","og_type":"article","og_title":"ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease","og_description":"ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its small\u2011molecule candidate RTX\u2011117 for the treatment of Charcot\u2011Marie\u2011Tooth (CMT) disease. The company plans to launch a Phase\u202f1 safety study in healthy volunteers in Q1\u202f2026, followed by a Phase\u202f1b\/2a trial in CMT patients as scheduled.","og_url":"https:\/\/flcube.com\/?p=43240","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-14T06:34:18+00:00","article_modified_time":"2025-10-14T06:34:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1403.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43240#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43240"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease","datePublished":"2025-10-14T06:34:18+00:00","dateModified":"2025-10-14T06:34:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43240"},"wordCount":352,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43240#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1403.webp","keywords":["Rare \/ orphan disease drugs","ReviR Therapeutics","Xtalpi"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43240#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43240","url":"https:\/\/flcube.com\/?p=43240","name":"ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43240#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43240#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1403.webp","datePublished":"2025-10-14T06:34:18+00:00","dateModified":"2025-10-14T06:34:19+00:00","description":"ReviR Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its small\u2011molecule candidate RTX\u2011117 for the treatment of Charcot\u2011Marie\u2011Tooth (CMT) disease. The company plans to launch a Phase\u202f1 safety study in healthy volunteers in Q1\u202f2026, followed by a Phase\u202f1b\/2a trial in CMT patients as scheduled.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43240#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43240"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43240#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1403.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1403.webp","width":1080,"height":608,"caption":"ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43240#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ReviR Therapeutics Secures FDA Orphan Drug Designation for RTX\u2011117, Targeting Charcot\u2011Marie\u2011Tooth Disease"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1403.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43240","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43240"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43240\/revisions"}],"predecessor-version":[{"id":43242,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43240\/revisions\/43242"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43241"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43240"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43240"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43240"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}